Naseema Gangat

Naseema Gangat

Auto-generated profile, based on publicly available information

Naseema Gangat

Division of Hematology Mayo Clinic Rochester Minnesota USA

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 September 2022 in Blood
Verified
Journal Article
Open access
PDF file
DADaniel A. Arber
Daniel A. Arber
AOAttilio Orazi
Attilio Orazi
RHRobert P. Hasserjian
Robert P. Hasserjian
MBMichael J. Borowitz
Michael J. Borowitz
KCKatherine R. Calvo
Katherine R. Calvo
ATAyalew Tefferi
Ayalew Tefferi
The classification of myeloid neoplasms and acute leukemias was last updated in 2016 within a collaboration between the World Health Organization (WHO), the Society for Hematopathology, and the European Association for Haematopathology. This collaboration was primarily based on input from a clinical advisory committees (CACs) composed of pathologists, hematologists, oncologists, geneticists, and bioinformaticians from around the world. The recent advances in our understanding of the biology of hematologic malignancies, the experience with the use of the 2016 WHO classification in clinical practice, and the results of clinical trials have indicated the need for further revising and updating the classification. As a continuation of this CAC-based process, the authors, a group with expertise in the clinical, pathologic, and genetic aspects of these disorders, developed the International Consensus Classification (ICC) of myeloid neoplasms and acute leukemias. Using a multiparameter approach, the main objective of the consensus process was the definition of real disease entities, including the introduction of new entities and refined criteria for existing diagnostic categories, based on accumulated data. The ICC is aimed at facilitating diagnosis and prognostication of these neoplasms, improving treatment of affected patients, and allowing the design of innovative clinical trials.

16 January 2020 in British Journal of Haematology
Verified
Journal Article
Closed access
PDF file
ATAyalew Tefferi
Ayalew Tefferi
PGPaola Guglielmelli
Paola Guglielmelli
TLTerra L. Lasho
Terra L. Lasho
GCGiacomo Coltro
Giacomo Coltro
CFChristy M. Finke
Christy M. Finke
AVAlessandro M. Vannucchi
Alessandro M. Vannucchi

24 August 2020 in American Journal of Hematology
Verified
Journal Article
Closed access
PDF file
EMErika Morsia
Erika Morsia
KMKristen McCullough
Kristen McCullough
MJMaansi Joshi
Maansi Joshi
JCJoselle Cook
Joselle Cook
HAHassan B. Alkhateeb
Hassan B. Alkhateeb
NGNaseema Gangat
Naseema Gangat

22 November 2017 in American Journal of Hematology
Verified
Journal Article
Closed access
PDF file
ATAyalew Tefferi
Ayalew Tefferi
MNMaura Nicolosi
Maura Nicolosi
MMMythri Mudireddy
Mythri Mudireddy
NSNatasha Szuber
Natasha Szuber
CFChristy M. Finke
Christy M. Finke
AVAlessandro Maria Vannucchi
Alessandro Maria Vannucchi

14 October 2022 in American Journal of Hematology
Verified
Journal Article
Closed access
JTJürgen Thiele
Jürgen Thiele
HKHans Michael Kvasnicka
Hans Michael Kvasnicka
AOAttilio Orazi
Attilio Orazi
UGUmberto Gianelli
Umberto Gianelli
NGNaseema Gangat
Naseema Gangat
ATAyalew Tefferi
Ayalew Tefferi

29 August 2018 in American Journal of Hematology
Verified
Journal Article
Closed access
PDF file
NSNatasha Szuber
Natasha Szuber
RVRangit R. Vallapureddy
Rangit R. Vallapureddy
DPDomenico Penna
Domenico Penna
TLTerra L. Lasho
Terra L. Lasho
CFChristy Finke
Christy Finke
ATAyalew Tefferi
Ayalew Tefferi